Studies completed in both humans and animals have shown that opioids have significant effects on the immune system via pharmacological interactions with the opioid receptor. However, the type of opioid receptor at which morphine binding produces changes in immune status has not been well characterized. To determine the type of opioid receptor involved in opioid-induced immune alterations, the present study assessed the effects of agonists selective for the µ-, δ-, and κ-opioid receptors. The site of action (i.e., peripheral vs central) at which opioids produce immune changes was investigated by injecting the agonists directly into the left lateral ventricle of the brain. ]enkephalin (DPDPE), a δ-opioid receptor agonist, or U69,593, a κ-receptor agonist. Immune assessments completed 1 h following drug administration showed that the µ-receptor selective agonist DAMGO produced a dose-dependent decrease in natural killer cell activity and T-lymphocyte proliferation to the mitogen concanavalin A (Con A); no immunological changes were found following DPDPE or U69,593 treatment. Calculation of the number of white blood cells per sample showed no differences between rats treated with saline and rats treated with any of the selective agonists. Administration of the opioid antagonist N-methylnaltrexone prior to DAMGO treatment attenuated the DAMGO-induced changes in immune status. Results from the present study indicate that the immunomodulatory effects of opioids can be attributed to interactions with the µ-opioid receptor.
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INTRODUCTION
Interest in the effects of drugs of abuse, especially opiates, on the immune system has increased with the progression of the AIDS epidemic. Studies completed in both humans and animals have shown that opioids have profound effects on the immune system. For example, heroin addicts exhibit an increased susceptibility to infections (Louria, Hensle, & Rose, 1967) as well as decreased T-lymphocyte proliferative responses to mitogen stimulation (Govitaprong, Suttitum, Kotchabhakdi, & Uneklabh, 1998) . Investigations in animals using the prototypic opioid morphine have also reported significant changes in immune status. Acute administration of morphine to rats has been shown to suppress T-and B-cell proliferation to mitogen stimulation (Bayer, Daussin, Hernandez, & Irvin, 1990; Bayer, Gastonguay, & Hernandez, 1992; Fecho, Dykstra, & Lysle, 1993; Lysle, Coussons, Watts, Bennett, & Dykstra, 1993) , decrease interleukin-2 and interferon production (Lysle et al., 1993) , suppress primary antibody production (Lockwood, Silber, Fleshner, Laudenslager, Watkins, & Maier, 1994) , and alter natural killer cell activity (Lysle et al., 1993; Shavit, DePaulis, Martin, Terman, Pechnick, Zane, Gale, & Liebeskind, 1986; Weber & Pert, 1989) .
Although the immune altering effects of morphine have been described, the site of action of morphine's effects remains unclear. One hypothesis is that morphine alters immune status via direct interactions with opioid receptors present on the sur-
